What Has Been The Historical And Current Growth Of The GLP-1 Receptor Agonist Market?
The glp-1 receptor agonist market has seen considerable growth due to a variety of factors.
• The market size of the GLP-1 receptor agonist has seen a consistent increase in recent years. The projected growth is from $13.58 billion in 2024 to $14.22 billion in 2025, with a compound annual growth rate (CAGR) of 4.7%. The growth experienced during the previous period can be traced back to factors like increased prevalence of diabetes, effective clinical results, heightened patient awareness and acceptance, worldwide health initiatives, and a preference among patients for injectable treatments.
What Is The Forecast For The GLP-1 Receptor Agonist Market Size?
The GLP-1 Receptor Agonist market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for GLP-1 receptor agonists is projected to witness significant expansion in the coming years, predicted to reach $17.72 billion by 2029, with a compound annual growth rate (CAGR) of 5.7%.
The anticipated expansion during the forecast period is ascribed to factors such as increased focus on lifestyle modification, growth in personalized healthcare strategies, broadened diagnostic scopes, the advent of new-age products, and incorporation into combination treatments. The forecast period is further likely to experience several trends including the launch of oral medication forms, emphasis on combined treatment options, strategic alliances and collaborations, policy procedures for reimbursements and accessibility, and patient-oriented approaches.
What Are The Essential Drivers Behind The Growth Of The GLP 1 Receptor Agonist Market?
The GLP-1 receptor agonist market is forecasted to grow, driven by the increasing incidence of diabetes. This chronic disease occurs when the pancreas is unable to produce enough insulin or the body fails to effectively use the insulin it generates. Diabetes mellitus, characterized by elevated blood sugar levels, is a metabolic disorder that can be managed with GLP-1 receptor agonist i.e it encourages the body to generate more insulin, subsequently reducing blood sugar. Hence, the growth of the diabetes epidemic predicts an expansion of the GLP-1 receptor agonist market. To illustrate, records from the UK's Office for Health Improvement and Disparities in March 2024 showed that from March 2022 to March 2023, there was a 22% increase in the number of individuals with type 1 diabetes who received all eight recommended care processes. Similarly, for type 2 diabetes, there was a 21% increase. Furthermore, the percentage of individuals meeting the target HbA1c levels reached an all-time high of 37.9% according to the National Diabetes Audit (NDA). As such, the expanding incidence of diabetes is fuelling the growth of the GLP-1 receptor agonist market.
How Is The Global GLP 1 Receptor Agonist Market Divided Into Key Segments?
The GLP-1 receptor agonist market covered in this report is segmented –
1) By Drug Class: Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Other Drugs
2) By Route Of Administration: Parenteral, Oral
3) By End Users: Hospitals, Surgical Clinics, Other Users
Subsegments:
1) By Exenatide: Byetta, Bydureon
2) By Liraglutide: Victoza, Saxenda
3) By Dulaglutide: Trulicity
4) By Lixisenatide: Adlyxin
5) By Other Drugs: Semaglutide, Tirzepatide, Others
Pre-Book The GLP 1 Receptor Agonist Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The GLP 1 Receptor Agonist Market?
One significant trend gathering momentum in the GLP-1 receptor agonist market is product innovation. Prominent firms in the GLP-1 receptor agonist sector are focusing these efforts to reinforce their standing in the marketplace. An illustration of this trend is presented by Eli Lilly and Company, an American pharmaceutical entity committed to enhancing lives through innovative medication, with the introduction of an FDA-approved new drug, Mounjaro, a GIP and GLP-1 receptor agonist, in May 2022. This drug employs a unique molecule that activates the body's receptors for incretin hormones GIP and GLP-1. This innovative medication is delivered via a pen auto-injector equipped with a non-visible, pre-attached needle, eliminating the need for patients to handle or see it. Moreover, it is offered in 6 different dose options.
Who Are the Key Players In The GLP 1 Receptor Agonist Market?
Major companies operating in the GLP-1 receptor agonist market include:
• Novo Nordisk A/S
• Sanofi SA
• Eli Lilly and Company
• AstraZeneca Inc.
• Boehringer Ingelheim International GmbH
• Hanmi Pharm Co. Ltd.
• Pfizer Inc.
• Amgen Inc.
• Innovent Biologics Inc.
• Jiangsu Hengrui Medicine Co.
• Sun Pharmaceuticals Industries Ltd.
• PegBio Co. Ltd.
• Zealand Pharma A/S
• Bristol-Myers Squibb Company
• Chongqing Lummy Pharmaceutical Co. Ltd.
• Daiichi Sankyo Company Limited
• Dong-A ST Co. Ltd.
• Eisai Co. Ltd.
• HanAll Biopharma Co. Ltd.
• Ipsen SA
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
What Are The Regional Insights Into The GLP 1 Receptor Agonist Market?
North America was the largest region in the GLP-1 receptor agonist market in 2024. Asia-Pacific is expected to be the fastest-growing region in the GLP-1 receptor agonist market report during the forecast period. The regions covered in the GLP-1 receptor agonist market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
